检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD)

Stephan Weidinger, Andrew Blauvelt,Kim Papp,Adam Reich,Chih-Hung Lee,Margitta Worm,Charles Lynde,Yoko Kataoka,Peter Foley, Christine Weber, Wanling Wong,Fabrice Hurbin,Natalie Rynkiewicz,Karl Yen, Xiaodan Wei, John T. O'Malley, Charlotte Bernigaud

BRITISH JOURNAL OF DERMATOLOGY（2024）

引用 0|浏览0
暂无评分
关键词
monoclonal antibody,anti-OX40L,phase 2b,biologic therapy,dose-ranging
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要